Financials data is unavailable for this security.
View more
Year on year Tonghua Dongbao Pharmaceutical Co Ltd had net income fall -26.17% from 1.58bn to 1.17bn despite a 10.69% increase in revenues from 2.78bn to 3.08bn.
| Gross margin | 77.31% |
|---|---|
| Net profit margin | 14.03% |
| Operating margin | 25.62% |
| Return on assets | 4.76% |
|---|---|
| Return on equity | 5.15% |
| Return on investment | 5.04% |
More ▼
Cash flow in CNYView more
In 2023, Tonghua Dongbao Pharmaceutical Co Ltd increased its cash reserves by 40.12%, or 316.14m. The company earned 861.52m from its operations for a Cash Flow Margin of 28.01%. In addition the company used 321.99m on investing activities and also paid 223.95m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 3.24 |
|---|---|
| Tangible book value per share | 2.50 |
More ▼
Balance sheet in CNYView more
| Current ratio | 4.30 |
|---|---|
| Quick ratio | 2.60 |
| Total debt/total equity | 0.0767 |
|---|---|
| Total debt/total capital | 0.0712 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -50.00% and -25.81%, respectively. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 2.56% |
|---|---|
| Div growth rate (5 year) | 4.56% |
| Payout ratio (TTM) | 145.16% |
| EPS growth(5 years) | 7.29 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -67.14 |
More ▼
